SurModics (SRDX) Reports Q4 EPS of $0.18

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. USO
2. MRVL
3. SPY
4. NVDA
5. BBIO
6. GOOGL
7. OPCH
8. AMD
9. CHRW
10. SKYD

Go back to SurModics (SRDX) Reports Q4 EPS of $0.18

Surmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance

November 8, 2017 7:30 AM EST

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and financial outlook for fiscal 2018.

Recent Highlights

First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil® Drug-Coated Balloon Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter Q4 2017 Revenue of $20.1 Million, up 10.5% EPS of $0.03, Non-GAAP EPS of $0.18

We are... More